Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.
Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.
Annexon has reported its second quarter 2020 financial results, highlighting a completed $263 million IPO in July and a private financing round in June that raised $96.8 million. The company is set to initiate four new clinical trials by year-end, including trials for ANX005 in expanded indications. As of June 30, 2020, cash and cash equivalents reached $124.8 million, a significant increase from $43.9 million at the end of 2019. However, net loss for the quarter amounted to $12.5 million, higher than the previous year's loss of $9.7 million.
Annexon, Inc. (Nasdaq: ANNX) has appointed Michael Overdorf as Chief Business Officer, effective July 30, 2020. Overdorf brings nearly 20 years of pharmaceutical experience, having spent 19 years at Eli Lilly in various leadership positions, including Corporate Business Development. His expertise will support Annexon's strategic commercial and business development efforts, especially concerning its promising pipeline of therapies targeting classical complement-mediated disorders. CEO Douglas Love expressed confidence in Overdorf's role to enhance corporate growth and patient access to therapeutic alternatives.
Annexon, Inc. (Nasdaq: ANNX) announced the closing of its initial public offering of 14,750,000 shares of common stock at $17.00 per share, generating approximately $250.8 million in gross proceeds. The stock began trading on July 24, 2020, with a 30-day option for underwriters to purchase an additional 2,212,500 shares. J.P. Morgan, BofA Securities, and Cowen are the joint book-running managers. This follows the effective registration of the offering on July 23, 2020. Annexon focuses on therapies for classical complement-mediated disorders, with an emphasis on autoimmune and neurodegenerative diseases.